PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

已收盘 09-05 16:00:00 EDT

16.47

-0.10

-0.60%

盘后16.29

-0.18-1.09%

19:56 EDT

最高16.83	最低16.18	成交量239.25万
今开16.55	昨收16.57	日振幅3.95%
总市值15.18亿	流通市值13.52亿	总股本9,217万
成交额3,930万	换手率2.91%	流通股本8,210万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":16.47,"timestamp":1757102400000,"preClose":16.57,"halted":0,"volume":2392521,"hourTrading":{"tag":"盘后","latestPrice":16.29,"preClose":16.47,"latestTime":"19:56 EDT","volume":39900,"amount":657009.83,"timestamp":1757116579384},"delay":0,"floatShares":82100696,"shares":92174000,"eps":-0.157563,"marketStatus":"已收盘","change":-0.1,"latestTime":"09-05 16:00:00 EDT","open":16.55,"high":16.83,"low":16.175,"amount":39301710.392463,"amplitude":0.039529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.157563,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1757318400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":16.57,"preHourTrading":{"tag":"盘前","latestPrice":16.66,"preClose":16.565,"latestTime":"09:23 EDT","volume":3004,"amount":49943.51268,"timestamp":1757078609235},"postHourTrading":{"tag":"盘后","latestPrice":16.29,"preClose":16.47,"latestTime":"19:56 EDT","volume":39900,"amount":657009.83,"timestamp":1757116579384},"volumeRatio":0.593108,"impliedVol":0.5021,"impliedVolPercentile":0.44},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2565587499","title":"港股异动 | 和誉-B(02256)高开逾6%破顶 公司近期迎多重利好 口服PD-L1联用戈来雷塞获批二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2565587499","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565587499?lang=zh_cn&edition=full","pubTime":"2025-09-05 09:30","pubTimestamp":1757035839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B高开逾6%，高见18.92港元创历史新高。消息面上，和誉近日宣布，在研口服PD-L1 抑制剂ABSK043 和艾力斯的KRAS G12C抑制剂戈来雷塞片联用治疗KRAS G12C突变的NSCLC的IND申请在中国获得批准。今年3月，公司和艾力斯就ABSK043达成合作协议，此次获批的是评估ABSK043和艾力斯的KRAS G12C抑制剂戈来雷塞片联用治疗KRASG12C突变的NSCLC的二期临床试验。8月27日公司回购20万股，8月28日又回购10万股。截至2025年6月30日，已累计回购954.5万股，合计7530万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","02256","LU1169590202.USD","BK1161","LU1169589451.USD","PD","LU2488822045.USD"],"gpt_icon":0},{"id":"2565914304","title":"PagerDuty's H2 Outlook Buoyed by Pricing Moves Despite User Reductions, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2565914304","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565914304?lang=zh_cn&edition=full","pubTime":"2025-09-05 02:14","pubTimestamp":1757009671,"startTime":"0","endTime":"0","summary":"PagerDuty  reported mixed fiscal Q2 results and guidance as businesses reduced user licenses and tightened technology budgets, RBC Capital Markets said Thursday in a report.Despite ongoing reductions in user volume, management sees improved performance and pricing changes as catalysts for H2 acceleration, RBC said.\"While we remain cautious on seat-based headwinds, we are encouraged by the pricing moves,\" RBC said.The company's appointment of Todd McNabb as chief revenue officer is expected to strengthen the go-to-market strategy in the medium term, the report said.RBC reduced its price target on PagerDuty stock to $18 from $20 on lower estimates and maintained its outperform rating.PagerDuty shares rose 5.6% in recent Thursday trading.Price: 16.47, Change: +0.88, Percent Change: +5.64","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"加拿大皇家银行表示，尽管用户减少，但PagerDuty的下半年前景仍受到定价变动的提振","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PD","LU1169589451.USD","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"1138284622","title":"异动解读 | 分析师上调目标价，PagerDuty盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284622","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138284622?lang=zh_cn&edition=full","pubTime":"2025-09-04 22:52","pubTimestamp":1756997543,"startTime":"0","endTime":"0","summary":"PagerDuty今日盘中大涨5%，引起投资者关注。据报道，多家券商对PagerDuty的投资评级和目标价进行了调整。尽管目标价有所下调，但分析师们仍然看好PagerDuty的长期发展前景。这些分析师评级的调整反映了市场对PagerDuty业务发展的持续关注。作为一家提供数字运营管理解决方案的公司，PagerDuty在当前数字化转型加速的背景下，其服务需求有望持续增长。投资者对公司未来的盈利能力保持乐观态度，推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"2564607303","title":"药捷安康-B(02617)：替恩戈替尼联用康方生物开坦尼®(卡度尼利，PD-1/CTLA-4)╱ 依达方®(依沃西，PD-1/VEGF)的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2564607303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564607303?lang=zh_cn&edition=full","pubTime":"2025-09-04 22:38","pubTimestamp":1756996699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司核心产品替恩戈替尼分别联用康方生物科技(开曼)有限公司开坦尼╱依达方的治疗晚期肝细胞癌的开放性、多中心II期临床研究，于近日完成首例患者给药。该试验的主要目标人群为既往未接受过针对肝细胞癌的全身抗肿瘤治疗或既往标准治疗失败后的晚期肝细胞癌患者。药捷安康已与康方生物订立合作协议，双方共同针对肝细胞癌领域开展临床联合用药开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","BK1574","LU0348783233.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0540923850.HKD","LU0634319403.HKD","BK1161","LU0561508036.HKD","LU0417516902.SGD","LU0348827113.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1169590202.USD","LU0348767384.USD","LU2778985437.USD","LU2488822045.USD","PD","LU1794554557.SGD","LU1720050803.USD","02617","LU0348784397.USD","LU0348825331.USD","LU0417516571.SGD","LU2476274720.SGD","LU0348735423.USD","LU0348766576.USD","LU1169589451.USD","BK4023"],"gpt_icon":1},{"id":"2564742713","title":"RBC Capital Adjusts PagerDuty Price Target to $18 From $20, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564742713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564742713?lang=zh_cn&edition=full","pubTime":"2025-09-04 20:30","pubTimestamp":1756989030,"startTime":"0","endTime":"0","summary":"PagerDuty (PD) has an average rating of overweight and mean price target of $18.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"RBC Capital将PagerDuty目标价从20美元调整至18美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PD"],"gpt_icon":0},{"id":"2564325557","title":"招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564325557?lang=zh_cn&edition=full","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","ADC.AU","BK1161","BK4080","LU1169589451.USD","BK4231","ADC","LU1169590202.USD","BK7095","PD","BK4023"],"gpt_icon":0},{"id":"2564328396","title":"研报掘金｜中金：上调和誉目标价至20港元 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2564328396","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564328396?lang=zh_cn&edition=full","pubTime":"2025-09-04 13:24","pubTimestamp":1756963469,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4023","LU1169589451.USD","LU0511384066.AUD","LU0175139822.USD","BK0239","LU2210150020.SGD","BK1161","LU1804176565.USD","LU0289739343.SGD","LU0109391861.USD","LU2265009873.SGD","LU2488822045.USD","02256","LU0289960550.SGD","LU0320765059.SGD","MSCI","BK4112","LU0672654240.SGD","LU1169590202.USD","LU1267930730.SGD","LU0708995401.HKD","LU0289961442.SGD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4588","PD","688578"],"gpt_icon":0},{"id":"2564319623","title":"PagerDuty Q2 Adj. EPS $0.30 Beats $0.21 Estimate, Sales $123.411M Miss $123.639M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2564319623","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564319623?lang=zh_cn&edition=full","pubTime":"2025-09-04 04:07","pubTimestamp":1756930048,"startTime":"0","endTime":"0","summary":"PagerDuty Q2 Adj. EPS $0.30 Beats $0.21 Estimate, Sales $123.411M Miss $123.639M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"PagerDuty第二季度调整后每股收益0.30美元，超出预期0.21美元，销售额1.23411亿美元，低于预期1.23639亿美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47485222/pagerduty-q2-adj-eps-0-30-beats-0-21-estimate-sales-123-411m-miss-123-639m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"PagerDuty Q2 Adj. EPS $0.30 Beats $0.21 Estimate, Sales $123.411M Miss $123.639M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD"],"gpt_icon":0},{"id":"2564489264","title":"港股异动 | 李氏大药厂(00950)尾盘涨超21% 上半年纯利增长7.5% 旗下PD-L1单抗国内近日获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2564489264","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564489264?lang=zh_cn&edition=full","pubTime":"2025-09-01 15:51","pubTimestamp":1756713060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，李氏大药厂尾盘涨超21%，截至发稿，涨16.02%，报21港元，成交额3195.61万港元。消息面上，李氏大药厂此前发布中期业绩，该集团取得收益6.95亿港元，同比增加5.5%；主要由集团产品组合稳健的销售表现所带动。值得注意的是，李氏大药厂7月底公告称，旗下子公司兆科肿瘤申报的抗PD-L1单克隆抗体索卡佐利单抗新适应症上市申请已获得批准。根据李氏大药厂公开资料可知，该药本次获批的适应症为联合化疗一线治疗广泛期小细胞肺癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1587","LU1169589451.USD","BK4023","06622","BK1574","LU1169590202.USD","PD","00950","BK1583"],"gpt_icon":0},{"id":"2562031124","title":"全球首个PD-L1 ADC启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2562031124","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562031124?lang=zh_cn&edition=full","pubTime":"2025-08-28 15:27","pubTimestamp":1756366034,"startTime":"0","endTime":"0","summary":"8月27日，全球临床试验收录网站显示，辉瑞启动了PD-L1 ADC药物PF-08046054的首个III期临床试验。该药物是首个进入III期阶段的PD-L1 ADC。截至2024年12月20日，共30例经治NSCLC患者入组接受1.5mg/kg PF-08046054治疗。结果显示，研究者评估的确认客观缓解率为26.7%，其中肿瘤表达PD-L1患者的cORR为32.0%。目前，全球共有5款在研PD-L1 ADC，包括PF-08046054、HLX43、AT-001、IMD2126以及Lanier Biotherapeutics公司的一款未有研发代号的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828154028a4a473c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["III","BK4134","BK4201","BK4080","ADC","BK4023","LU1169590202.USD","BK4231","E","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2562170031","title":"辉瑞Sigvotatug Vedotin启动III期临床 适应症为PD-L1高表达的非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2562170031","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562170031?lang=zh_cn&edition=full","pubTime":"2025-08-28 12:03","pubTimestamp":1756353780,"startTime":"0","endTime":"0","summary":"本次试验主要目的为证明Sigvotatug Vedotin + 帕博利珠单抗在延长OS和BICR评估的PFS方面优于帕博利珠单抗单药；次要目的包括比较两组间BICR评估的客观缓解率，评价其他有效性指标，评估安全性和耐受性特征，以及评估联合给药时的药代动力学和免疫原性。Sigvotatug Vedotin为生物制品，适应症为PD-L1高表达的非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082812485395021e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","LU0225771236.USD","LU0321505868.SGD","E","IE00B19Z3581.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0122379950.USD","BK4007","SG9999001176.USD","LU0234572021.USD","LU1169590202.USD","LU1883839398.USD","BK4599","LU0225284248.USD","BK4134","PD","LU0306807586.USD","BK4585","BK4550","LU1894683348.USD","III","LU1066053197.SGD","IE000M9KFDE8.USD","SG9999013999.USD","BK4534","IE00B19Z3B42.SGD","BK4201","BK4533","BK4588","BK4592","LU0985481810.HKD","LU0058720904.USD","PFE","LU0868494617.USD","BK4568","LU0456855351.SGD","LU0170899867.USD","LU1066051498.USD","SG9999002232.USD","BK4581","IE0002270589.USD","LU0306806265.USD","LU1057294990.SGD","LU1894683264.USD","IE00BLSP4452.SGD","LU1169589451.USD","LU0321505439.SGD","IE00BLSP4239.USD","BK4023"],"gpt_icon":1},{"id":"2562476162","title":"复宏汉霖(2696.HK)：中金首次覆盖，给予“跑赢行业”评级，目标价102.91港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562476162","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562476162?lang=zh_cn&edition=full","pubTime":"2025-08-27 08:35","pubTimestamp":1756254935,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2236285917.USD","BK4080","LU0320765646.SGD","BK1161","LU1201861249.SGD","BK1574","LU0106831901.USD","LU2125154935.USD","IE00BSNM7G36.USD","LU2360032135.SGD","02696","LU0130517989.USD","BK4504","LU1162221912.USD","LU0052756011.USD","LU1169590202.USD","ADC","BK4588","LU2462157665.USD","LU1169589451.USD","LU0130102774.USD","LU1791807156.HKD","LU1244550221.USD","BK4566","LU1244550577.SGD","159399","LU2417539215.USD","BK4207","159992","BK4231","BK4585","LU0477156953.USD","LU0648001328.SGD","LU0098860793.USD","PD","06978","LU0128525689.USD","LU1668664300.SGD","LU2456880835.USD","LU0072461881.USD","BK4023","LU0162691827.USD","LU2125154778.USD","LU1244550494.USD","BK4534","BK4559","LU0310800965.SGD","LU1267930227.SGD","LU0170899867.USD","LU1366192091.USD"],"gpt_icon":0},{"id":"2562215760","title":"医药行业：创新药黄金赛道梳理之PD-1(PD-L1)/VEGF双抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2562215760","media":"平安证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562215760?lang=zh_cn&edition=full","pubTime":"2025-08-25 00:00","pubTimestamp":1756051200,"startTime":"0","endTime":"0","summary":"建议关注迈瑞医疗、联影医疗、开立医疗等。行业要闻荟萃1、荣昌生物眼科创新药授权参天制药；2、石药集团HER2双抗拟纳入优先审评；3、康方生物IL-17A单抗治疗强直性脊柱炎III期研究成功；4、第一三共/阿斯利康TROP2 ADC在华获批上市。港股医药板块中，上周医药板块上涨0.93%，同期恒生综指上涨0.69%；医药行业在11个行业中涨跌幅排名第8位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825150620a6f9c897&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","BK4023","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2561224724","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)用于治疗晚期非小细胞肺癌的国际多中心2期临床研究完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2561224724","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561224724?lang=zh_cn&edition=full","pubTime":"2025-08-22 17:03","pubTimestamp":1755853413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，一项注射用HLX43在晚期非小细胞肺癌患者中开展的国际多中心2期临床研究已完成美国首例患者给药。本研究的主要研究目的为评估HLX43在晚期非小细胞肺癌中的临床疗效;主要研究终点为由盲态独立中心审查委员会根据RECISTv1.1标准评估的客观缓解率。HLX43为靶向PD-L1的抗体偶联药物。截至本公告日，于全球范围内尚无靶向PD-L1的抗体偶联药物获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","LU1169589451.USD","PD","BK1161","02696","BK4023"],"gpt_icon":0},{"id":"2561682094","title":"研报掘金丨开源证券：华东医药创新药收入快速增长，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2561682094","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561682094?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:22","pubTimestamp":1755768169,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09939","159992","000963","BK4023","BK0183","159938","BK4590","LU1969619763.USD","ADC","06978","BK0187","BK0132","BK0209","BK0196","BK4144","BK4231","BK0188","161027","LU2328871848.SGD","BK1515","BK1161","PD","LU1169590202.USD","BK4080","BK0175","GLP","LU1169589451.USD","BK1574"],"gpt_icon":0},{"id":"2560170789","title":"和誉-B(02256)：和誉医药的口服PD-L1抑制剂ABSK043与艾力斯的 KRAS G12C抑制剂枸橼酸戈来雷塞片联合用药治疗NSCLC的 IND申请获CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2560170789","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560170789?lang=zh_cn&edition=full","pubTime":"2025-08-20 19:27","pubTimestamp":1755689260,"startTime":"0","endTime":"0","summary":"和誉-B(02256)公布，公司附属公司和誉医药在研的口服PD-L1抑制剂ABSK...","market":"fut","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","CDE","BK1161","BK1515","LU1169589451.USD","LU1223083913.SGD","LU1223082196.USD","BK4023","LU1169590202.USD","688578","02256","BK1574","LU1223082519.USD","BK0239","PD","159938","LU2488822045.USD","BK4017"],"gpt_icon":0},{"id":"2559060996","title":"默克公司的可瑞达（Keytruda）获加拿大卫生部批准用于治疗伴有 PD-L1 表达的头颈部鳞状细胞癌（HNSCC）。","url":"https://stock-news.laohu8.com/highlight/detail?id=2559060996","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559060996?lang=zh_cn&edition=full","pubTime":"2025-08-13 19:09","pubTimestamp":1755083374,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0266013472.USD","LU0203347892.USD","LU0211331839.USD","IE00BBT3K403.USD","LU0965509283.SGD","LU1066053197.SGD","BK4023","LU1061106388.HKD","MRK","LU1989771016.USD","SG9999002224.SGD","LU0238689110.USD","SG9999015341.SGD","LU0106261372.USD","LU0122379950.USD","LU0098860793.USD","LU2106854487.HKD","LU0234572021.USD","LU1037948897.HKD","LU1430594728.SGD","LU2361044865.SGD","SGXZ57979304.SGD","LU1037948541.HKD","LU2023250504.SGD","LU2361044949.HKD","IE00BLSP4452.SGD","LU0965509101.SGD","IE00BSNM7G36.USD","LU0861579265.USD","LU0985320562.USD","LU1066051811.HKD","LU1066051498.USD","LU1585245621.USD","LU2461242641.AUD","LU0265550946.USD","LU0320765646.SGD","BK4007","BK4559","LU1571399168.USD","LU1989772840.SGD","LU1169590202.USD","LU1066051225.USD","LU1929549753.HKD","LU2023250843.SGD","LU0070302665.USD","LU1093756325.SGD","LU1699723380.USD","LU2112291526.USD","LU1069347547.HKD","PD"],"gpt_icon":0},{"id":"2559608787","title":"国金证券：从IL-2双抗 看TAA、细胞及趋化因子的PD-1升级新方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2559608787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559608787?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:55","pubTimestamp":1755075315,"startTime":"0","endTime":"0","summary":"从肿瘤抗原TAA到IL-2因子类加持PD-1升级的新分子，信达生物PD-1/IL-2在ASCO首次发布数据，在免疫耐受肺癌与黑色素瘤以及冷肿瘤肠癌3项适应症中皆取得靓丽早期数据。除了PD-1等免疫检测点抑制剂与抗TAA的组合，PD-1等与白介素、TGFβ等细胞因子的组合发力，以及对TME相关因子的开发或成为肿瘤免疫治疗领域下一个重要赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1329073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348784397.USD","600109","BK0012","IE00B5MMRT66.SGD","BK1583","BK0201","BK0276","01801","09926","BK1574","PD","BK0028","LU0348783233.USD","LU2488822045.USD","IE00B543WZ88.USD","06990","LU0417516571.SGD","LU1169590202.USD","LU1794554557.SGD","LU0196878994.USD","LU1969619763.USD","BK1161","IE00BPRC5H50.USD","LU1169589451.USD","BK0183","BK4023","LU2328871848.SGD","BK1589","LU1720050803.USD","BK0188"],"gpt_icon":0},{"id":"2559608323","title":"恒瑞医药：子公司SHR-A2102及阿得贝利单抗注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2559608323","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559608323?lang=zh_cn&edition=full","pubTime":"2025-08-13 16:40","pubTimestamp":1755074443,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1997244956.HKD","09939","BK0028","BK0239","LU1328615791.USD","BK4231","161726","01276","LU1655091616.SGD","LU2580892789.USD","BK1574","BK1515","BK0012","BK4023","LU0405327494.USD","LU2488822045.USD","BK0060","LU2495084118.USD","BK4080","159938","LU0405327148.USD","LU1169590202.USD","LU1255011170.USD","LU2328871848.SGD","399441","LU1064130708.USD","LU1169589451.USD","BK1191","LU1064131003.USD","PD","BK0196","BK0188","LU2580892862.HKD","BK0183","LU1997245094.SGD","LU1969619763.USD","LU1997245177.USD","ADC","LU2148510915.USD","LU2543165471.USD","BK1161","600276"],"gpt_icon":0},{"id":"2558342976","title":"【券商聚焦】华福证券维持康方生物(09926)“买入”评级 看好PD-1和VEGF靶点的广谱泛癌作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2558342976","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558342976?lang=zh_cn&edition=full","pubTime":"2025-08-11 15:14","pubTimestamp":1754896442,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华福证券研报指，康方生物 AK112进度全球领先，有望占据全球二代IO市场的最大份额。从进度来看，目前公司AK112国内已有2项适应症获批上市，1项纳入国家医保目录，是目前全球唯一成药的PD-1/VEGF双抗。假设公司AK112国内已开展3期的适应症顺利开展国际3期后，经风险调整海外销售峰值约197亿美金。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1963817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","PD","161027"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":0.0635},{"period":"3month","weight":0.0141},{"period":"6month","weight":-0.0531},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0926}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0337},{"period":"3month","weight":0.0834},{"period":"6month","weight":0.1271},{"period":"1year","weight":0.1782},{"period":"ytd","weight":0.1076}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.045759},{"month":2,"riseRate":0.5,"avgChangeRate":-0.032478},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018297},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.049825},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.007313},{"month":6,"riseRate":0.714286,"avgChangeRate":0.021791},{"month":7,"riseRate":0.571429,"avgChangeRate":0.017838},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.000522},{"month":9,"riseRate":0,"avgChangeRate":-0.113769},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037852},{"month":11,"riseRate":0.666667,"avgChangeRate":0.066825},{"month":12,"riseRate":0.5,"avgChangeRate":0.034253}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}